Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders

The novelty of the 2023 National Guidelines for Lipid Metabolism Disorders is presented regarding the categorization of cardiovascular risk, target and optimal levels of blood lipids, diagnosis and therapeutic approaches to the treatment of dyslipidemia.

Saved in:
Bibliographic Details
Main Authors: I. V. Sergienko, M. V. Ezhov
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2023-12-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/5688
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850025483577589760
author I. V. Sergienko
M. V. Ezhov
author_facet I. V. Sergienko
M. V. Ezhov
author_sort I. V. Sergienko
collection DOAJ
description The novelty of the 2023 National Guidelines for Lipid Metabolism Disorders is presented regarding the categorization of cardiovascular risk, target and optimal levels of blood lipids, diagnosis and therapeutic approaches to the treatment of dyslipidemia.
format Article
id doaj-art-03a7cac463e04ac1a05c1becdea7484c
institution DOAJ
issn 1560-4071
2618-7620
language Russian
publishDate 2023-12-01
publisher «FIRMA «SILICEA» LLC
record_format Article
series Российский кардиологический журнал
spelling doaj-art-03a7cac463e04ac1a05c1becdea7484c2025-08-20T03:00:50Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202023-12-01284S10.15829/1560-4071-2023-56883976Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism DisordersI. V. Sergienko0M. V. Ezhov1E.I. Chazov National Medical Research Center of CardiologyE.I. Chazov National Medical Research Center of CardiologyThe novelty of the 2023 National Guidelines for Lipid Metabolism Disorders is presented regarding the categorization of cardiovascular risk, target and optimal levels of blood lipids, diagnosis and therapeutic approaches to the treatment of dyslipidemia.https://russjcardiol.elpub.ru/jour/article/view/5688lipid metabolism disordersdyslipidemiaatherosclerosislow-density lipoprotein cholesteroltriglycerideslipoprotein(a)inclisiranfenofibrate
spellingShingle I. V. Sergienko
M. V. Ezhov
Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders
Российский кардиологический журнал
lipid metabolism disorders
dyslipidemia
atherosclerosis
low-density lipoprotein cholesterol
triglycerides
lipoprotein(a)
inclisiran
fenofibrate
title Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders
title_full Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders
title_fullStr Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders
title_full_unstemmed Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders
title_short Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders
title_sort review and analysis of 2023 clinical guidelines for lipid metabolism disorders
topic lipid metabolism disorders
dyslipidemia
atherosclerosis
low-density lipoprotein cholesterol
triglycerides
lipoprotein(a)
inclisiran
fenofibrate
url https://russjcardiol.elpub.ru/jour/article/view/5688
work_keys_str_mv AT ivsergienko reviewandanalysisof2023clinicalguidelinesforlipidmetabolismdisorders
AT mvezhov reviewandanalysisof2023clinicalguidelinesforlipidmetabolismdisorders